Ventyx Crohn's trial misses primary endpoint

 The Phase 2 trial of VTX958 in Crohn’s disease did not meet its primary endpoint of change from baseline in mean CDAI score in either VTX958 dose group

Both VTX958 dose groups achieved nominal statistical significance on the key secondary endpoint of endoscopic response as measured by SES-CD

At this time, Ventyx does not anticipate conducting additional clinical trials of VTX958 with internal resources

https://www.globenewswire.com/news-release/2024/07/29/2920240/0/en/Ventyx-Biosciences-Announces-Results-from-the-Phase-2-Trial-of-VTX958-in-Participants-with-Moderately-to-Severely-Active-Crohn-s-Disease.html